First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma: a cost-effectiveness analysis

BACKGROUND: The CheckMate-649 trial compared nivolumab plus chemotherapy (NC) with chemotherapy alone as first-line treatment for advanced gastric cancer (GC), gastroesophageal junction cancer (GEJC), and esophageal adenocarcinoma (EAC) and showed significant benefits to progression-free survival an...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Xueqiong, Zhang, Mingming, Li, Na, Zheng, Bin, Liu, Maobai, Song, Xiaobing, Cai, Hongfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201153/
https://www.ncbi.nlm.nih.gov/pubmed/37223263
http://dx.doi.org/10.1177/17588359231171038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201153/
https://www.ncbi.nlm.nih.gov/pubmed/37223263
http://dx.doi.org/10.1177/17588359231171038

Ejemplares similares